---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-065908"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-05-26T10:09:56+00:00"
generated_at: "2026-05-26T10:16:37.515883+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs

## Summary
- Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.
- Achieved ~90% mean reduction in Lp(a) and ApoB, supporting unified LDLR upregulation mechanism.
- Well-tolerated at therapeutically relevant dose 1.5 mg/kg; no adverse observations in ongoing GLP toxicology.
- Plans to submit CTN in Australia by mid-2026; first-in-human HeFH trial later in 2026; early human PoC data by end of 2026.
- Received positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.

## SEC filing metadata
- accession: 0001104659-26-065908
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-05-26T10:09:56+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000110465926065908/0001104659-26-065908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000110465926065908/tm2615565d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-065908
- JSON: https://secwatch.observer/filing/0001104659-26-065908.json
- Plain text: https://secwatch.observer/filing/0001104659-26-065908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.